Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00831129

A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs (SIROCO)

Effects of Simvastatin and Rosiglitazone Combination in Patients With the Metabolic Syndrome.

Sponsor: GlaxoSmithKline

Interventions Placebo Rosiglitazone Rosiglitazone Simvastatin

Updated 6 times since 2017 Last updated: Dec 19, 2016 Started: Sep 30, 2006 Primary completion: Mar 31, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Pre-diabetes and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States